IndustryCompany release

MiMedx investor deck details Sanara MedTech deal under FTC Second Request review

🇺🇸 Mimedx Group, Inc. (MDXG) · Wed 28 Oct 2026

MiMedx's October 2026 investor presentation says its proposed Sanara MedTech acquisition faces an FTC Second Request and HSR waiting period, with Hayfin debt financing committed.

MiMedx Group has published an October 2026 investor presentation that describes its proposed acquisition of Sanara MedTech. Much of the document consists of disclaimers and cautionary statements, so the detail it offers on the transaction is limited.

According to the presentation, the deal is under review by the US Federal Trade Commission, which has issued a Second Request. The Hart-Scott-Rodino (HSR) waiting period is also referenced. By way of context, a Second Request is a formal demand for additional information and typically extends an antitrust review beyond the initial HSR waiting period.

The transaction is backed by a debt financing commitment from Hayfin. The commitment carries a ticking fee, a charge that generally accrues while funds are committed but not yet drawn. The summary available does not give the size of the financing, the fee rate or an expected closing date.

MiMedx also points to several growth drivers. These include the Medicare spending reform environment and enrolment in randomised controlled trials of EPIEFFECT and CHORIOFIX. The company further cites a surgical portfolio that includes HELIOGEN, AMNIOFIX and AMNIOEFFECT.

What it means for your team

  • Market-access teams in wound care and surgical biologics should note that MiMedx names Medicare spending reform as part of its operating environment.
  • Regulatory and competition-affairs staff should track the FTC Second Request, as it signals a more extended review before the Sanara MedTech deal can proceed.
  • Clinical and evidence teams may watch enrolment progress in the EPIEFFECT and CHORIOFIX randomised controlled trials, which the company links to growth.
  • The deal's financing terms, including the ticking fee, mean timing of the FTC review may carry cost implications for the companies involved.

Company's press release (SEC filing): Mimedx Group, Inc. ↗

Article written by VigiEye from the official source (Mimedx Group, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →